Company: IMCR
Filing Date: 2025-03-17
Form Type: 424B7
Source: 0001140361-25-008917
Chunk: 78

Company: Immunocore Holdings plc
Filing Date: 2025-03-17
Form: 424B7
Chunk 78
---
 a filing has actually been made;provided, that no person or group shall be deemed to be the beneficial owner of any securities tendered pursuant to a tender or exchange offer made by or on behalf of such “person” or “group” until such tendered securities are accepted for purchase or exchange under such offer; |

| (2) | the consummation of (A) any recapitalization, reclassification or change of our ordinary shares or ADSs (other than a change to nominal value, or changes resulting from a subdivision or combination) as a result of which our ordinary shares or ADSs would be converted into, or exchanged for, shares of any class, other |

S-43

TABLE OF CONTENTS

securities, other property or assets; (B) any share exchange, consolidation or merger of us pursuant to which our ordinary shares or ADSs will be converted into cash, securities or other property or assets; or (C) any sale, lease or other transfer in one transaction or a series of transactions of all or substantially all of the consolidated assets of us and our subsidiaries, taken as a whole, to any person other than one or more of our direct or indirect wholly owned subsidiaries; provided, however, that a transaction described in clause (A) or (B) in which the holders of all classes of our common equity immediately prior to such transaction own, directly or indirectly, more than 50% of all classes of common equity of the continuing or surviving corporation or transferee or the parent thereof immediately after such transaction in substantially the same proportions (relative to each other) as such ownership immediately prior to such transaction shall not be a fundamental change pursuant to this clause (2);

| (3) | our shareholders approve any plan or proposal for the liquidation or dissolution of us; or |

| (4) | our ADSs (or other common equity or ADSs in respect of the common equity underlying the notes) cease to be listed or quoted on any of the Nasdaq Global Select Market, the New York Stock Exchange or the Nasdaq Global Market (or any of their respective successors). |

A transaction or transactions described in clause (2) above will not constitute a fundamental change, however, if at least 90% of the consideration received or to be received by holders of our ADSs, excluding cash payments for fractional ADSs and cash payments made in respect of dissenters’ appraisal rights, in connection with such transaction or transactions consists of ordinary shares, corporate common equity or ADSs in respect of ordinary